Summary of study ST001515

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001022. The data can be accessed directly via it's Project DOI: 10.21228/M8KT26 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Download all metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST001515
Study TitleA Metabolomic Signature of Glucagon Action in Healthy Individuals with Overweight/Obesity Humans
Study SummaryObjective: We sought to identify the circulating metabolites that would serve as markers of glucagon action. Design: In this study, we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight/obesity. Participants were randomized to either glucagon (12.5 ng/kg/min) (GCG 12.5) or glucagon (25 ng/kg/min) GCG 25 or a placebo control were included. A comprehensive metabolomics analysis was then performed from plasma isolated at several time points during the infusion to identify markers of glucagon activity.
Institute
Translational Research Institute- AdventHealth Orlando
Last NameWhytock
First NameKatie
Address301 E Princeton St, Orlando, FL, 32804
EmailKatie.Whytock@adventhealth.com
Phone321-945-9982
Submit Date2020-10-26
Num Groups3
Total Subjects33
Raw Data AvailableYes
Raw Data File Type(s)excel
Analysis Type DetailOther
Release Date2020-12-01
Release Version1
Katie Whytock Katie Whytock
https://dx.doi.org/10.21228/M8KT26
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR001022
Project DOI:doi: 10.21228/M8KT26
Project Title:Effects of glucagon infusion on plasma metabolome in individuals with overweight/obesity
Project Summary:Objective: We sought to identify the circulating metabolites that would serve as markers of glucagon action. Design: In this study, we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight/obesity. Participants were randomized to either glucagon (12.5 ng/kg/min) (GCG 12.5) or glucagon (25 ng/kg/min) GCG 25 or a placebo control were included. A comprehensive metabolomics analysis was then performed from plasma isolated at several time points during the infusion to identify markers of glucagon activity.
Institute:Translational Research Institute- AdventHealth Orlando
Last Name:Whytock
First Name:Katie
Address:301 E Princeton St, FL, USA, 32804
Email:Katie.Whytock@adventhealth.com
Phone:3219459982
Funding Source:Sanofi

Subject:

Subject ID:SU001589
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Group TIMEPOINT
SA127238FLHP-00174-01High-Dose -0.5HR
SA127239FLHP-00028-01High-Dose -0.5HR
SA127240FLHP-00062-01High-Dose -0.5HR
SA127241FLHP-00111-01High-Dose -0.5HR
SA127242FLHP-00012-01High-Dose -0.5HR
SA127243FLHP-00090-01High-Dose -0.5HR
SA127244FLHP-00057-01High-Dose -0.5HR
SA127245FLHP-00037-01High-Dose -0.5HR
SA127246FLHP-00151-01High-Dose -0.5HR
SA127247FLHP-00006-01High-Dose -0.5HR
SA127197FLHP-00055-01High-Dose +23HR POST INFUSION
SA127198FLHP-00016-01High-Dose +23HR POST INFUSION
SA127199FLHP-00186-01High-Dose +23HR POST INFUSION
SA127200FLHP-00061-01High-Dose +23HR POST INFUSION
SA127201FLHP-00148-01High-Dose +23HR POST INFUSION
SA127202FLHP-00025-01High-Dose +23HR POST INFUSION
SA127203FLHP-00039-01High-Dose +23HR POST INFUSION
SA127204FLHP-00088-01High-Dose +23HR POST INFUSION
SA127205FLHP-00110-01High-Dose +23HR POST INFUSION
SA127206FLHP-00011-01High-Dose +23HR POST INFUSION
SA127207FLHP-00040-01High-Dose +47HR POST INFUSION
SA127208FLHP-00171-01High-Dose +47HR POST INFUSION
SA127209FLHP-00027-01High-Dose +47HR POST INFUSION
SA127210FLHP-00015-01High-Dose +47HR POST INFUSION
SA127211FLHP-00056-01High-Dose +47HR POST INFUSION
SA127212FLHP-00184-01High-Dose +47HR POST INFUSION
SA127213FLHP-00086-01High-Dose +47HR POST INFUSION
SA127214FLHP-00152-01High-Dose +47HR POST INFUSION
SA127215FLHP-00010-01High-Dose +47HR POST INFUSION
SA127216FLHP-00109-01High-Dose +47HR POST INFUSION
SA127217FLHP-00054-01High-Dose +4HR POST INFUSION
SA127218FLHP-00150-01High-Dose +4HR POST INFUSION
SA127219FLHP-00036-01High-Dose +4HR POST INFUSION
SA127220FLHP-00173-01High-Dose +4HR POST INFUSION
SA127221FLHP-00024-01High-Dose +4HR POST INFUSION
SA127222FLHP-00087-01High-Dose +4HR POST INFUSION
SA127223FLHP-00014-01High-Dose +4HR POST INFUSION
SA127224FLHP-00008-01High-Dose +4HR POST INFUSION
SA127225FLHP-00113-01High-Dose +4HR POST INFUSION
SA127226FLHP-00183-01High-Dose +4HR POST INFUSION
SA127227FLHP-00063-01High-Dose +4HR POST INFUSION
SA127228FLHP-00147-01High-Dose +71HR POST INFUSION
SA127229FLHP-00058-01High-Dose +71HR POST INFUSION
SA127230FLHP-00112-01High-Dose +71HR POST INFUSION
SA127231FLHP-00060-01High-Dose +71HR POST INFUSION
SA127232FLHP-00172-01High-Dose +71HR POST INFUSION
SA127233FLHP-00038-01High-Dose +71HR POST INFUSION
SA127234FLHP-00023-01High-Dose +71HR POST INFUSION
SA127235FLHP-00182-01High-Dose +71HR POST INFUSION
SA127236FLHP-00089-01High-Dose +71HR POST INFUSION
SA127237FLHP-00009-01High-Dose +71HR POST INFUSION
SA127248FLHP-00053-01High-Dose BASELINE
SA127249FLHP-00013-01High-Dose BASELINE
SA127250FLHP-00114-01High-Dose BASELINE
SA127251FLHP-00007-01High-Dose BASELINE
SA127252FLHP-00185-01High-Dose BASELINE
SA127253FLHP-00035-01High-Dose BASELINE
SA127254FLHP-00175-01High-Dose BASELINE
SA127255FLHP-00059-01High-Dose BASELINE
SA127256FLHP-00026-01High-Dose BASELINE
SA127257FLHP-00091-01High-Dose BASELINE
SA127258FLHP-00149-01High-Dose BASELINE
SA127304FLHP-00133-01Low-Dose -0.5HR
SA127305FLHP-00146-01Low-Dose -0.5HR
SA127306FLHP-00190-01Low-Dose -0.5HR
SA127307FLHP-00181-01Low-Dose -0.5HR
SA127308FLHP-00034-01Low-Dose -0.5HR
SA127309FLHP-00156-01Low-Dose -0.5HR
SA127310FLHP-00139-01Low-Dose -0.5HR
SA127311FLHP-00066-01Low-Dose -0.5HR
SA127312FLHP-00115-01Low-Dose -0.5HR
SA127313FLHP-00121-01Low-Dose -0.5HR
SA127314FLHP-00101-01Low-Dose -0.5HR
SA127315FLHP-00078-01Low-Dose -0.5HR
SA127259FLHP-00118-01Low-Dose +23HR POST INFUSION
SA127260FLHP-00100-01Low-Dose +23HR POST INFUSION
SA127261FLHP-00077-01Low-Dose +23HR POST INFUSION
SA127262FLHP-00153-01Low-Dose +23HR POST INFUSION
SA127263FLHP-00141-01Low-Dose +23HR POST INFUSION
SA127264FLHP-00180-01Low-Dose +23HR POST INFUSION
SA127265FLHP-00031-01Low-Dose +23HR POST INFUSION
SA127266FLHP-00192-01Low-Dose +23HR POST INFUSION
SA127267FLHP-00137-01Low-Dose +23HR POST INFUSION
SA127268FLHP-00065-01Low-Dose +23HR POST INFUSION
SA127269FLHP-00134-01Low-Dose +23HR POST INFUSION
SA127270FLHP-00123-01Low-Dose +23HR POST INFUSION
SA127271FLHP-00124-01Low-Dose +47HR POST INFUSION
SA127272FLHP-00191-01Low-Dose +47HR POST INFUSION
SA127273FLHP-00179-01Low-Dose +47HR POST INFUSION
SA127274FLHP-00120-01Low-Dose +47HR POST INFUSION
SA127275FLHP-00144-01Low-Dose +47HR POST INFUSION
SA127276FLHP-00154-01Low-Dose +47HR POST INFUSION
SA127277FLHP-00135-01Low-Dose +47HR POST INFUSION
SA127278FLHP-00099-01Low-Dose +47HR POST INFUSION
SA127279FLHP-00076-01Low-Dose +47HR POST INFUSION
SA127280FLHP-00033-01Low-Dose +47HR POST INFUSION
SA127281FLHP-00067-01Low-Dose +47HR POST INFUSION
SA127282FLHP-00155-01Low-Dose +4HR POST INFUSION
SA127283FLHP-00102-01Low-Dose +4HR POST INFUSION
SA127284FLHP-00064-01Low-Dose +4HR POST INFUSION
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 187

Collection:

Collection ID:CO001584
Collection Summary:Samples were homogenized and subjected to methanol extraction then split into aliquots for analysis
Sample Type:Blood (plasma)

Treatment:

Treatment ID:TR001604
Treatment Summary:Study subjects were admitted to the Clinical Research Unit (CRU) at the Translational Research Institute (TRI) at AdventHealth for 5 overnight stays. The first 2 overnight stays were used as baseline. On the 2nd day (Day -1), a baseline blood draw (-24 hours) was performed. On Day 1, a blood draw was again taken approximately 30 minutes prior to the start of the glucagon infusion. The study subjects began a ramped infusion (first 4 hours) of either saline (Placebo), Low Dose Glucagon (12.5ng/kg/min) or High Dose Glucagon (25ng/kg/min) for the next 72 hours (Inpatient). The Glucagon (GlucaGen, Novo Nordisk, Bagsværd Denmark) was administered under an FDA-approved IND (#136634). Intravenous (IV) bags of the study medication were hung together on an IV pole and changed out every 24 hours to provide a continuous infusion. With the exception of the 4-hour time point, all draws were performed in the overnight fasted state.

Sample Preparation:

Sampleprep ID:SP001597
Sampleprep Summary:Briefly, samples were homogenized and subjected to methanol extraction then split into aliquots for analysis by ultrahigh performance liquid chromatography/mass spectrometry (UHPLC/MS) in the positive (two methods) and negative (two methods) mode. Metabolites were then identified by automated comparison of ion features to a reference library of chemical standards followed by visual inspection for quality control.

Combined analysis:

Analysis ID AN002511 AN002512 AN002513 AN002514
Analysis type MS MS MS MS
Chromatography type Reversed phase Reversed phase Reversed phase HILIC
Chromatography system Waters Acquity Waters Acquity Waters Acquity Waters Acquity
Column Waters Acquity BEH C18 (100 x 2mm, 1.7um) Waters Acquity BEH C18 (100 x 2mm, 1.7um) Waters Acquity BEH C18 (100 x 2mm, 1.7um) Waters Acquity BEH Amide (150 x 2.1mm, 1.7um)
MS Type ESI ESI ESI ESI
MS instrument type Orbitrap Orbitrap Orbitrap Orbitrap
MS instrument name Thermo Q Exactive Orbitrap Thermo Q Exactive Orbitrap Thermo Q Exactive Orbitrap Thermo Q Exactive Orbitrap
Ion Mode POSITIVE POSITIVE NEGATIVE NEGATIVE
Units scaled units scaled units scaled units scaled units

Chromatography:

Chromatography ID:CH001835
Instrument Name:Waters Acquity
Column Name:Waters Acquity BEH C18 (100 x 2mm, 1.7um)
Chromatography Type:Reversed phase
  
Chromatography ID:CH001836
Instrument Name:Waters Acquity
Column Name:Waters Acquity BEH C18 (100 x 2mm, 1.7um)
Chromatography Type:Reversed phase
  
Chromatography ID:CH001837
Instrument Name:Waters Acquity
Column Name:Waters Acquity BEH C18 (100 x 2mm, 1.7um)
Chromatography Type:Reversed phase
  
Chromatography ID:CH001838
Instrument Name:Waters Acquity
Column Name:Waters Acquity BEH Amide (150 x 2.1mm, 1.7um)
Chromatography Type:HILIC

MS:

MS ID:MS002329
Analysis ID:AN002511
Instrument Name:Thermo Q Exactive Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:Proprietary analytical software for integration and peak picking
Ion Mode:POSITIVE
  
MS ID:MS002330
Analysis ID:AN002512
Instrument Name:Thermo Q Exactive Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:Proprietary analytical software for integration and peak picking
Ion Mode:POSITIVE
  
MS ID:MS002331
Analysis ID:AN002513
Instrument Name:Thermo Q Exactive Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:Proprietary analytical software for integration and peak picking
Ion Mode:NEGATIVE
  
MS ID:MS002332
Analysis ID:AN002514
Instrument Name:Thermo Q Exactive Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:Proprietary analytical software for integration and peak picking
Ion Mode:NEGATIVE
  logo